Developing therapeutic antibodies against SARS-CoV-2
In April 2020, we began to leverage our platform’s drug discovery capabilities to discover fully human neutralizing antibodies to potentially speed the recovery from or prevent COVID-19 under a memorandum of understanding with Amgen.
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.
Adaptive will extend its high-throughput immune medicine platform to rapidly screen the massive genetic diversity of the B-cell repertoire. This enables us to identify tens of thousands of naturally occurring BCRs from survivors of COVID-19 to characterize the best antibodies that neutralize SARS-CoV-2 and potentially other related coronaviruses. We recently entered into an agreement with Amgen, whereby Amgen has the option to review Adaptive’s neutralizing antibody candidates and take them forward into development and commercialization.